NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

Executive Summary

• NetraMark Holdings Inc. announced a signed contract with a leading global biopharmaceutical company to analyze Phase 2 clinical trial data for depression using its NetraAI platform.
• The engagement expands NetraMark’s portfolio of AI‑driven projects in central nervous system (CNS) disorders and is expected to generate revenue while showcasing the commercial applicability of its proprietary AI methodology.
• The collaboration aims to identify patient subpopulations most likely to benefit from treatment, improve dosing decisions, and increase overall trial success rates for the sponsor’s program.

Key Details

• Contract Scope: NetraMark will deploy its proprietary AI methodology to analyze multi‑dimensional clinical data from the sponsor’s Phase 2 depression trial, focusing on patient phenotyping, response pattern evaluation, and hypothesis generation.
• Target Therapeutic Area: Depression (CNS disorder) – part of a broader portfolio that includes other CNS indications.
• Technology Leveraged: NetraAI platform, which uses a dynamical systems framework to handle small, complex clinical datasets, separating explainable from unexplainable patient subsets to avoid over‑fitting and improve insight quality.
• Expected Benefits for Sponsor:
• Identification of high‑effect‑size patient subpopulations.
• Data‑driven guidance on dosing strategies and trial design refinements.
• Enhanced likelihood of trial success through precision‑trial insights.
• Strategic Significance: Demonstrates growing demand from pharmaceutical companies for AI tools that address patient heterogeneity, positioning NetraMark as a key service provider in the clinical‑trial optimization market.
• Financial Impact (not disclosed): While specific fees or revenue terms were not provided, the agreement is anticipated to contribute positively to NetraMark’s near‑term and long‑term earnings outlook.

Notable Quotes

“We believe this engagement reflects the demand from pharmaceutical companies to better understand the patient heterogeneity in clinical trials,” said George Achilleos, Chief Executive Officer of NetraMark.
“By analyzing this Phase 2 dataset, we aim to identify the patient subpopulations most likely to benefit from treatment and provide insights that may inform our sponsor’s future study design with greater precision and confidence.”